Beacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep Disorders
April 30 2024 - 9:00AM
Beacon Biosignals, the leader in at-home EEG and computational
neurodiagnostics, announced a collaboration with Takeda to conduct
at-home sleep monitoring to support clinical trials for sleep
disorders leveraging Beacon’s neurophysiology platform, including
the FDA-cleared Dreem 3S EEG headband, AI-powered analytics, and
clinico-EEG database.
Understanding the importance of sleep-related disturbances is
critical to improving the diagnostic journey of sleep disorders
such as narcolepsy and enabling more personalized treatment
options. Quantitative sleep data have historically been difficult
to collect and analyze at the speed and scale necessary to support
clinical development. This collaboration enables Takeda to collect
laboratory-quality sleep data from a patient’s home,
longitudinally, and at-scale using Beacon’s advanced wearable sleep
EEG hardware, AI-powered analytics, and clinical operations
services.
“Takeda is committed to developing life-transforming therapies
for areas of highest unmet need, including narcolepsy and other
sleep-wake disorders. In partnering with Beacon, we will now have
access to real-time, longitudinal sleep data that better reflects
the daily burden of living with these disorders,” said Elena
Koundourakis, head of the Orexin Franchise Development and
Neuroscience Portfolio Strategy at Takeda. “The Beacon Platform
will be used to inform our clinical trial designs including
defining quantitative, digital endpoints based on objective
measures of sleep patterns, which could support more tailored
treatment approaches and improve the diagnostic journey for
patients.”
The Beacon Platform facilitates comprehensive insights into
sleep and wake brain function. The Dreem 3S headband, which
recently earned FDA 510(k) medical device clearance, enables
longitudinal sleep data collection from patients in the comfort of
their home and via self-application without the need for
specialized technologists. Collecting these data remotely
alleviates the patient burden of travelling to a sleep lab and may
improve the diagnostic journey by enabling faster sleep testing.
Additionally, Beacon’s advanced machine learning algorithms, which
are also FDA 510(k)-cleared, rapidly analyze EEG data to capture
validated clinical trial endpoints and score sleep stages with
equivalent performance to human experts. In this collaboration with
Takeda, Beacon’s AI-powered technologies establish a foundation for
improved diagnostics and support the development of interventions
for disorders with excessive daytime sleepiness or disturbed
nighttime sleep.
Jacob Donoghue, MD, PhD, CEO of Beacon, expressed excitement
about the collaboration, stating, "Beacon is thrilled to work with
Takeda to support the advancement of therapies that can improve the
lives of patients. Sleep is fundamental to brain health and
together we’re setting a new standard for rigorously measuring
sleep in clinical trials. By improving the patient experience and
operationalizing at-home sleep assessments at scale, we are
generating unprecedented, high-quality data on brain function
during drug development. This paves the way for real-world use in
clinical diagnostics across neurological and psychiatric
indications."
About Beacon Biosignals
Beacon Biosignals is the leading at-home EEG platform for
precision drug development. Its FDA 510(k)-cleared Dreem 3S EEG
headband algorithms enable and accelerate research and development
of treatments that transform the lives of patients with
neurological, psychiatric, and sleep disorders. Beacon’s
Clinico-EEG database contains over 100,000 patients’ brain activity
data, and its cloud-native analytics platform empowers rapid
interrogation of brain activity to support retrospective and
prospective studies. For more information, visit
https://beacon.bio. Follow us on X (@Biosignals) or LinkedIn
(https://www.linkedin.com/company/beacon-biosignals).
Beacon Biosignals contact information:info@beacon.bio
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/620b2787-0030-4845-bd35-c711c1194a97